Santosa Katherine B, Chen Xiaoxue, Qi Ji, Ballard Tiffany N S, Kim Hyungjin M, Hamill Jennifer B, Bensenhaver Jessica M, Pusic Andrea L, Wilkins Edwin G
Ann Arbor, Mich.; and New York, N.Y.
From the Section of Plastic Surgery, Department of Surgery, and the Department of Biostatistics, University of Michigan Health System; Center for Statistical Consultation and Research, University of Michigan; and Plastic and Reconstructive Surgery, Memorial Sloan Kettering Cancer Center.
Plast Reconstr Surg. 2016 Oct;138(4):761-769. doi: 10.1097/PRS.0000000000002534.
The ideal timing of postmastectomy radiation therapy (PMRT) in the setting of two-stage implant-based breast reconstruction remains unclear. In this cohort study, the authors sought to determine whether complication rates differed between patients who received PMRT following tissue expander placement (TE-XRT) and those who received PMRT after exchange for permanent implants (Implant-XRT) utilizing using prospective, multicenter data.
Eligible patients in the Mastectomy Reconstruction Outcomes Consortium study from 11 institutions across North America were included in the analysis. All patients had at least 6-month follow-up after their last intervention (i.e., implant exchange for TE-XRT patients, and radiation for Implant-XRT patients). Complications including seroma, hematoma, infection, wound dehiscence, capsular contracture, and implant loss were recorded.
The authors identified a total of 150 patients who underwent immediate, two-stage implant-based breast reconstruction and received PMRT. Of these, there were TE-XRT 104 patients (69.3 percent) and 46 (30.7 percent) Implant-XRT patients. There were no differences in the incidence of any complications or complications leading to reconstructive failure between the two cohorts. After adjusting for patient characteristics and site effect, the timing of PMRT (i.e., TE-XRT versus Implant-XRT) was not a significant predictor in the development of any complication, a major complication, or reconstructive failure.
In the setting of PMRT and two-stage implant-based reconstruction, patients who received PMRT after expander placement (TE-XRT) did not have a higher incidence or increased odds of developing complications than those who received PMRT after exchange for a permanent implant (Implant-XRT).
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
在基于植入物的两阶段乳房重建中,乳房切除术后放疗(PMRT)的理想时机仍不明确。在这项队列研究中,作者试图利用前瞻性多中心数据,确定在组织扩张器置入后接受PMRT的患者(TE-XRT)和更换为永久性植入物后接受PMRT的患者(植入物-XRT)之间的并发症发生率是否存在差异。
纳入了北美11家机构的乳房切除术后重建结果联盟研究中的符合条件的患者进行分析。所有患者在最后一次干预后至少随访6个月(即TE-XRT患者进行植入物更换,植入物-XRT患者进行放疗)。记录包括血清肿、血肿、感染、伤口裂开、包膜挛缩和植入物丢失在内的并发症。
作者共确定了150例接受即刻两阶段基于植入物的乳房重建并接受PMRT的患者。其中,TE-XRT患者104例(69.3%),植入物-XRT患者46例(30.7%)。两组之间任何并发症或导致重建失败的并发症发生率均无差异。在调整患者特征和部位效应后,PMRT的时机(即TE-XRT与植入物-XRT)不是任何并发症、主要并发症或重建失败发生的显著预测因素。
在PMRT和两阶段基于植入物的重建中,扩张器置入后接受PMRT的患者(TE-XRT)与更换为永久性植入物后接受PMRT的患者(植入物-XRT)相比,并发症发生率没有更高,发生并发症的几率也没有增加。
临床问题/证据水平:治疗性,III级。